Clinical Trials Logo
  1. Home
  2. Optic Glioma
  3. NCT01800032

PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

Plexiform Neurofibroma Clinical Trial

Official title:
Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography- Magnetic Resonance Imaging (FDG-PET-MRI) in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

Clinical Trial Summary

This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibromatosis-1 (NF1) associated optic glioma and plexiform neurofibroma (PN). Subjects will undergo FDG-PET-MRI scans in place of standard of care imaging at 0 and 12 months, unless more frequent imaging is clinically indicated. Subjects and their family caregivers will also undergo serial interviews and complete questionnaires related to the psychosocial aspects of NF1.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01800032
Study type Observational
Source UNC Lineberger Comprehensive Cancer Center
Contact
Status Completed
Phase
Start date January 16, 2013
Completion date December 5, 2019
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03962543 - MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Phase 2
Completed NCT03326388 - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Phase 1/Phase 2
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Active, not recruiting NCT03231306 - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Phase 2
Active, not recruiting NCT00326872 - AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine Phase 2
Active, not recruiting NCT04954001 - Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Phase 1/Phase 2
Recruiting NCT05913037 - FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Phase 3
Completed NCT00727233 - Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Phase 1
Active, not recruiting NCT03820778 - Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 N/A
Recruiting NCT06379230 - A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
Active, not recruiting NCT00924196 - Natural History Study of Patients With Neurofibromatosis Type I
Completed NCT00396019 - Study of PEG-Intron for Plexiform Neurofibromas Phase 2
Active, not recruiting NCT03363217 - Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. Phase 2
Not yet recruiting NCT06188741 - Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 Phase 2
Completed NCT01412892 - Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Phase 2